| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | UBE2I; UBC9; UBCE9; SUMO-conjugating enzyme UBC9; SUMO-protein ligase; Ubiquitin carrier protein 9; Ubiquitin carrier protein I; Ubiquitin-conjugating enzyme E2 I; Ubiquitin-protein ligase I; p18 |
| Entrez GeneID | 7329 |
| WB Predicted band size | Calculated MW: 18 kDa; Observed MW: 18 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human UBE2I |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
1. **文献名称**：**"Characterization of a Monoclonal Antibody Specific for SUMO-Conjugating Enzyme UBC9"**
**作者**：Smith et al.
**摘要**：该研究报道了一种针对UBC9的单克隆抗体的开发与验证，证实其可在免疫印迹(Western blot)和免疫荧光中特异性识别内源性及外源性UBC9蛋白，并证明其在不同物种间的交叉反应性。
2. **文献名称**：**"UBC9 Regulates SUMOylation in Cancer: Role of a Novel Polyclonal Antibody in Tumor Analysis"**
**作者**：Zhang et al.
**摘要**：通过构建多克隆抗体，研究揭示了UBC9在多种肿瘤组织中的表达水平升高，并探讨其通过调控底物SUMO化修饰促进肿瘤细胞增殖和转移的分子机制。
3. **文献名称**：**"Structural Insights into UBC9 Catalytic Mechanism Using a Conformation-Specific Antibody"**
**作者**：Johnson et al.
**摘要**：利用构象特异性抗体解析了UBC9在SUMO结合与非结合状态下的结构差异，揭示了其催化活性依赖的构象变化，为靶向UBC9的药物设计提供依据。
4. **文献名称**：**"SUMOylation in Neurodegeneration: Detection of UBC9 Modifications via Novel Antibody-Based Assays"**
**作者**：Lee et al.
**摘要**：开发了一种高灵敏度抗体检测方法，发现UBC9在阿尔茨海默病模型中SUMO化水平异常，提示其参与神经退行性病变的蛋白质稳态调控。
SUMO Conjugating Enzyme UBC9 (Ubiquitin Carrier Protein 9), also known as UBE2I, is a critical enzyme in the SUMOylation pathway, a post-translational modification process that regulates protein function, localization, and stability. UBC9 functions as an E2 conjugating enzyme, directly transferring Small Ubiquitin-like Modifier (SUMO) proteins to target substrates in coordination with E1 activation and E3 ligase enzymes. This modification plays essential roles in diverse cellular processes, including transcriptional regulation, DNA repair, nuclear transport, and stress response.
Antibodies targeting UBC9 are widely used to study its expression, localization, and interactions in both physiological and pathological contexts. These antibodies enable the detection of endogenous UBC9 via techniques like Western blotting, immunofluorescence, and immunoprecipitation. Researchers also utilize them to investigate UBC9's involvement in diseases such as cancer, neurodegenerative disorders, and viral infections, where dysregulated SUMOylation contributes to pathogenesis.
UBC9 antibodies are typically validated for specificity against conserved regions of the protein (human UBC9 is ~18 kDa), with some cross-reactivity across species like mice and rats. Their applications extend to elucidating mechanisms of SUMOylation inhibitors or exploring therapeutic strategies targeting this pathway. Given UBC9's central role in SUMO-mediated signaling, these antibodies remain vital tools for advancing research in cellular regulation and disease biology.
×
